IBIO

$0.82+2.95%visit website

iBio, Inc.

Market Cap

$53M

Live price × SEC shares (Aug 27, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.50

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

529.6

TTM to Jun 2026 · revenue

Flagged input, hover for details

P/B

0.6

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q1 FY2026 Sep 30, 2025	Q2 FY2026 Dec 31, 2025	Q3 FY2026 Mar 31, 2026	Q4 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	100	0	0	0	100
Research & development	3,550	4,280	3,254	8,559	19,643
Total operating expenses	6,051	9,445	8,365	11,380	35,241
Operating income	(5,951)	(9,445)	(8,365)	(11,380)	(35,141)
Interest expense	36.0	41.0	22.0	(46.0)	53.0
Pretax income					(33,044)
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(5,720)	(8,993)	(7,730)	(10,601)	(33,044)
EPS (basic) ($)	(0.11)	(0.09)	(0.06)		(0.32)
EPS (diluted) ($)	(0.11)	(0.09)	(0.06)		(0.32)
Weighted avg. shares (basic)	52,981	99,133	119,600
Weighted avg. shares (diluted)	52,981	99,133	119,600

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-K filed Aug 28, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 60 more quarters, back to Sep 2010, with Tormere Pro.

Corporate Events (8-K)

19 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Oct 19, 2026 accepted 8:16 PM ET	5.02Officer / director change5.03Bylaws / fiscal year5.07Shareholder vote	Document SEC ↗
Oct 13, 2026 accepted 12:25 PM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗
Sep 14, 2026 accepted 8:16 PM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗
Aug 28, 2026 accepted 12:30 PM ET	2.02Earnings release	Document SEC ↗
Aug 4, 2026 accepted 11:05 AM ET	5.02Officer / director change8.01Other events	Document SEC ↗
Jul 17, 2026 accepted 8:08 PM ET	5.08Director nominations8.01Other events	Document SEC ↗
Jul 1, 2026 accepted 11:33 AM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗
May 12, 2026 accepted 8:15 PM ET	2.02Earnings release	Document SEC ↗
May 8, 2026 accepted 8:16 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
Apr 17, 2026 accepted 9:13 PM ET	8-K/A 8.01Other events	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

39%

W/W -24.6pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-03-26	2026-03-27	Banjak Marc	Chief Legal Officer	Purchase	13.9K	$1.65	$23K	25.0K	View
2026-03-19	2026-03-23	Duran Felipe	Chief Financial Officer	Purchase	24.8K	$2.02	$50K	36.0K	View
2026-03-19	2026-03-23	Brenner Martin	Director & See Remarks	Purchase	12.3K	$2.02	$25K	30.7K	View

Recent News

iBio to Participate in Upcoming Investor Conferences

Yahoo · 2026-11-02

iBio executives will appear at investor conferences in Boston, London and New York.

Stock Titan · 2026-11-02

iBio Inc (IBIO) Stock Forecast & Analyst Ratings

Moomoo · 2026-11-02

Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor

Benzinga · 2026-10-29

iBio, Inc. (NASDAQ:IBIO) Stock Has Average Price Target of $6.00 According to Analysts

MarketBeat · 2026-10-23

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · 2026-10-20

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

Yahoo · 2026-10-13

iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity

Benzinga · 2026-10-13

iBio, Inc. Stock 12‑Month Price Target Raised to $5.6, Implies 509% Upside

TradingView · 2026-10-09

iBio, Inc. (IBIO) Presents at 2026 EASD Annual Meeting - Slideshow

SeekingAlpha · 2026-10-07

iBio, Inc. (IBIO) Presents at 2026 EASD Annual Meeting - Slideshow (NASDAQ:IBIO) 2026-10-07

Seeking Alpha · 2026-10-07

iBio stock initiated at buy by H.C. Wainwright with $7 target

Investing.com · 2026-09-17

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

Yahoo Finance · 2026-09-01

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Yahoo Finance · 2026-08-28

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Yahoo Finance · 2026-07-01

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-03-26	Banjak Marc	P	12,500	$20,531.25
2026-03-26	Banjak Marc	P	1,434	$2,523.84
2026-03-19	Duran Felipe	P	24,835	$50,131.93
2026-03-19	Brenner Martin	P	12,336	$24,918.72

IBIO

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

iBio, Inc. (IBIO)

Reporting Insiders

Factor Profile

Corporate Events (8-K)